Merck’s top-line came in weaker than expected as Healthcare faced harsher business conditions. Not infected, but affected by fewer doctor visits. Profitability was in line and street expectations were met. Life Science continued to see strong demand in Process Solutions, and Performance Materials was clearly helped by the strong contribution from Versum at all levels. Management’s guidance update confirms our strong view on the company.
